Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease
- 646 Downloads
Fibroblast growth factor 23 (FGF23) and soluble α-Klotho are emerging potential biomarkers of phosphorus and vitamin D metabolism which change in concentration in early chronic kidney disease (CKD) in order to maintain normal phosphorus levels. Tubular reabsorption of phosphate (TRP) has been commonly used to assess renal tubular phosphate transport. The aim of this study was to evaluate the usefulness of TRP as a surrogate marker of parameters of CKD-mineral bone disease (CKD-MBD) in CKD.
A cross-sectional study was performed in 93 stable patients with predialysis CKD stage 1–5. In all patients, TRP, estimated glomerular filtration rate (eGFR), calcium, phosphate, intact parathyroid hormone (iPTH), 25-hydroxyvitamin D, serum FGF23 and urine soluble α-Klotho levels were measured.
As renal function declined, TRP significantly decreased (P < 0.001; r = 0.763) and both iPTH and serum FGF23 increased (P < 0.001; r = −0.598, P < 0.001; r = −0.453, respectively). The prevalence of hyperphosphatemia, secondary hyperparathyroidism, FGF23 excess and abnormal TRP increased progressively with declining eGFR. Although TRP level changed later than FGF23, abnormal levels of both TRP and FGF23 were observed earlier than changes in iPTH and serum phosphate. Decreased TRP was found to be independently associated with decreased eGFR and increased iPTH but was not associated with urine soluble α-Klotho or serum FGF23 level in multiple linear regression analysis.
TRP is a simple, useful and cost-saving surrogate marker of the assessment of altered mineral metabolism in CKD patients and can be used as an alternative to serum FGF23, especially for mild to moderate renal insufficiency.
KeywordsRenal failure Chronic Phosphates Tubular reabsorption of phosphate Fibroblast growth factor 23 Klotho
The authors would like to thank Professor S. W. Kim of the Division of Urology, The Catholic University of Korea and Professor B. S. Choi of Seogang University for their valuable discussions. This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (C·W.P; A111055).
Conflict of interest
The authors have declared that no conflicts of interest exist.
- 6.Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, et al. Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol. 2012;16(5):722–9. doi: 10.1007/s10157-012-0621-7.CrossRefPubMedGoogle Scholar
- 8.Walton Rj, Fau-Bijvoet OL, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2(7929):309–10.Google Scholar
- 10.Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31–8. doi: 10.1038/sj.ki.5002009.CrossRefPubMedGoogle Scholar
- 11.Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26(2):584–91. doi: 10.1093/ndt/gfq419.CrossRefPubMedCentralPubMedGoogle Scholar
- 24.Kuwahara N, Sasaki S, Kobara M, Nakata T, Tatsumi T, Irie H, et al. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol. 2008;123(2):84–90. doi: 10.1016/j.ijcard.2007.02.029.CrossRefPubMedGoogle Scholar